Werewolf Therapeutics, Inc. (HOWL) Q1 2024 Earnings
HOWL·Reported May 3, 2024·Before market open
Werewolf Therapeutics, Inc. reported Q1 2024 revenue of $742.0K, missed analyst consensus of $1.5M by $715.4K. Diluted EPS came in at $-0.39, missed the $-0.35 consensus by $0.04.
Revenue
$742.0Kmissed by $715.4K
Consensus: $1.5MDiluted EPS
$-0.39missed by $0.04
Consensus: $-0.35
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Werewolf Therapeutics, Inc.'s Q1 2024 earnings report.
Werewolf Therapeutics, Inc. (HOWL) reported Q1 2024 earnings on May 3, 2024 before market open.
Werewolf Therapeutics, Inc. reported revenue of $742.0K and diluted EPS of $-0.39 for Q1 2024.
Revenue missed the consensus estimate of $1.5M by $715.4K. EPS missed the consensus estimate of $-0.35 by $0.04.
You can read the 10-Q periodic report (0001785530-24-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.